Status:
UNKNOWN
A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer
Lead Sponsor:
Hebei Tumor Hospital
Conditions:
Gastric Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
A study of Raltitrexed plus Docetaxel versus Docetaxel as second-line chemotherapy in subjects with Gastric Cancer.The purpose of this study is to compare the activity of Raltitrexed plus Docetaxel ve...
Eligibility Criteria
Inclusion
- Signed informed consent form
- Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-2;
- Histologically or cytologically confirmed gastric cancer;
- The first-line chemotherapy failure (required containing 5-fluorouracil)
- At least have one measurable disease(according to RECIST, Response Evaluation Criteria in Solid Tumors )
- Life expectancy of at least 3 months;
Exclusion
- Received any prior treatment including Raltitrexed;
- Active or uncontrolled infection;
- Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial;
- Pregnant or lactating women.
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2017
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01836120
Start Date
April 1 2013
End Date
June 1 2017
Last Update
April 19 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hebei Tumor Hospital
Shijiazhuang, Hebei, China, 050011